对新型林纳利普丁类似物进行全面的实验和计算评估:合成,DFT计算,分子建模,以及体外抗癌/抗氧化活性

相关实验视频

Updated: Mar 10, 2026

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

8.8K

Ömer Dilek1, Dilek Bahar2, Tolga Acar Yeşil3

  • 1Central Research Laboratory Application and Research Center, Isparta University of Applied Sciences, Isparta, Turkey.

Computational biology and chemistry
|March 9, 2026
PubMed
概括

基于林格利普丁的新型胺衍生物显示出有前途的抗癌活性. 化合物3h对A549和DLD1癌细胞表现出显著的抗增殖作用,表明具有多功能药物开发潜力.

关键词:
2D NMR 是一个二维的NMR.抗氧化剂是一种抗氧化剂.亚胺矿是一种亚胺矿.细胞毒性 细胞毒性在体研究中,研究人员进行了体研究.林纳格利普丁 (Linagliptin) 是一种药物.

更多相关视频

An In Ovo Model for Testing Insulin-mimetic Compounds06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.2K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.6K

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
827
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K